Literature DB >> 1067159

Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy.

Y Uzuka, S K Liong, S Yamagata.   

Abstract

A regime of treatment of acute non-lymphoblastic leukemia in adult, employing DMCP protocol, especially two step method consisting of daunorubicin, cytosine arabinoside, 6-mercaptopurine and prednisolone is described. Out of 32 adult patients with ANLL treated with DCMP regime 26 (81.3%) achieved complete remission. The median durations of complete remission and survival were 53 weeks and 54 weeks, respectively. The longest duration of complete remission was more than 220 weeks, and 3 cases are still maintaining initial complete remission more than 3 years.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1067159     DOI: 10.1620/tjem.118.suppl_217

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

1.  A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation.

Authors:  R Ohno; K Yamada; T Masaoka; T Ohshima; I Amaki; Y Hirota; N Horikoshi; A Horiuchi; K Imai; I Kimura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.

Authors:  Atsushi Wakita; Shigeki Ohtake; Satoru Takada; Fumiharu Yagasaki; Hirokazu Komatsu; Yasushi Miyazaki; Kohmei Kubo; Yukihiko Kimura; Akihiro Takeshita; Yoko Adachi; Hitoshi Kiyoi; Takuhiro Yamaguchi; Minoru Yoshida; Kazunori Ohnishi; Shuichi Miyawaki; Tomoki Naoe; Ryuzo Ueda; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2012-05-26       Impact factor: 2.490

3.  Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hitoshi Kiyoi; Yasushi Miyazaki; Hirokazu Okumura; Shin Matsuda; Tadashi Nagai; Yuji Kishimoto; Masaya Okada; Masatomo Takahashi; Hiroshi Handa; Jin Takeuchi; Shinichi Kageyama; Norio Asou; Fumiharu Yagasaki; Yasuhiro Maeda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2010-03       Impact factor: 2.490

4.  Remission-induction regimens in acute nonlymphocytic leukemia.

Authors:  D C Brennan; J P Lewis
Journal:  West J Med       Date:  1980-10

5.  Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.

Authors:  J K Rees; R M Sandler; J Challener; F G Hayhoe
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.